Search Results

You are looking at 1 - 10 of 456 items for :

  • molecular epidemiology x
  • All content x
Clear All
Open access

Marc Sinotte, François Rousseau, Pierre Ayotte, Eric Dewailly, Caroline Diorio, Yves Giguère, Sylvie Bérubé, and Jacques Brisson

analogs – a brief overview . Molecular and Cellular Biochemistry 253 247 – 254 . Berube S Diorio C Verhoek-Oftedahl W Brisson J 2004 Vitamin D, calcium, and mammographic breast densities . Cancer Epidemiology, Biomarkers and Prevention

Free access

Marc T Goodman, Galina Lurie, Pamela J Thompson, Katharine E McDuffie, and Michael E Carney

XO 2007 Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women . Cancer Epidemiology, Biomarkers and Prevention 16 943 – 949 . Yager JD Liehr JG 1996 Molecular mechanisms of estrogen carcinogenesis

Free access

Andrew G Renehan, Michelle Harvie, and Anthony Howell

gained prominence in cancer epidemiology when investigators from the Health Professionals Study demonstrated that concentrations of IGF-I, measured in prospectively collected plasma, were positively associated, while concentrations of IGFBP-3 were

Free access

Jay H Fowke, Charles E Matthews, Herbert Yu, Qiuyin Cai, Sarah Cohen, Maciej S Buchowski, Wei Zheng, and William J Blot

factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum . Cancer Epidemiology, Biomarkers & Prevention 16 1017 – 1022 . Berrigan D Potischman N Dodd KW Hursting SD

Free access

Suman Rice and Saffron A Whitehead

known about the epidemiology of breast cancer until 20th century although, interestingly, in 1713 an Italian doctor and a founder of occupational medicine, Bernardino Ramazzini, reported the virtual absence of cervical cancer and relatively high

Free access

L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell

two of these molecular targets. In this regard, cyclin D1 was shown to inhibit the activity of two gene products involved in fat metabolism, the CCAAT/enhancer binding protein (CEBP)-β ( Lamb et al. 2003 ) and peroxisome proliferator

Free access

Christy G Woolcott, Yurii B Shvetsov, Frank Z Stanczyk, Lynne R Wilkens, Kami K White, Christian Caberto, Brian E Henderson, Loïc Le Marchand, Laurence N Kolonel, and Marc T Goodman

primary breast cancer to the end of follow-up (December, 2006) and had plasma available for analysis. Diagnoses were identified by linkage of the MEC to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program that covers

Free access

Laura Sterian Ward

the molecular approaches to thyroid tumor diagnosis. In addition, some of the molecular markers presented have been long studied, such as RAS, RET, PPARG/PAX8, PIK3CA, TP53, TSHR, PTEN, GNAS, CTNNB1, AKT1 , whereas others have recently emerged as

Free access

Carlien Leyssens, Lieve Verlinden, and Annemieke Verstuyf

types of cancer cells are used. This is explained by different molecular mechanisms that 1,25(OH) 2 D 3 causes in different cell types, so therefore 1,25(OH) 2 D 3 is thought to induce cell-specific gene regulations ( Krishnan et al . 2004 ). Clearly

Free access

Dong-Yeop Shin, Soyeun Kim, Sunhoo Park, Jae Soo Koh, Cheol Hyeon Kim, HeeJong Baek, Sung Hyun Yang, and Im Il Na

, molecular evidence of enhanced catabolic inactivation and growth inhibition in response to vitamin D in EGFR -mutant cells supports an inhibitory role of vitamin D, particularly in EGFR -mutant tumors ( Zhang et al . 2013 ). Taken together, these results